Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Target Price at $19.67

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $18.00.

Several equities analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Tvardi Therapeutics to a “strong sell” rating in a report on Saturday, July 18th. HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday, July 8th.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TVRD. Geode Capital Management LLC acquired a new position in Tvardi Therapeutics during the 2nd quarter worth about $2,617,000. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $39,000. New York State Common Retirement Fund bought a new position in shares of Tvardi Therapeutics in the second quarter worth about $92,000. Marshall Wace LLP bought a new position in shares of Tvardi Therapeutics in the second quarter worth about $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $43,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Price Performance

Tvardi Therapeutics stock opened at $2.00 on Thursday. The stock has a fifty day moving average price of $2.68 and a two-hundred day moving average price of $3.32. Tvardi Therapeutics has a 52-week low of $1.50 and a 52-week high of $43.65. The firm has a market capitalization of $18.76 million, a P/E ratio of -0.65 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). On average, equities research analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current fiscal year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.